Pharming Group N.V. (ENXTAM:PHARM) is looking acquisitions. During the company?s first half 2023 results call, Jeroen Wakkerman, Chief Financial Officer said that ?We continue to look at investments on acquisitions and in-licensing of mid- to late-stage opportunities in rare diseases to build the company further?.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9 EUR | +2.16% | +2.16% | -12.71% |
Apr. 22 | Pharming Group to Buy Back EUR123 Million of Bonds due 2025 | MT |
Apr. 18 | Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.71% | 647M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- PHARM Stock
- News Pharming Group N.V.
- Pharming Seeks Acquisitions